|
Post by prcgorman2 on Apr 9, 2019 20:28:54 GMT -5
Well, there was some speculation Paul Allen was behind RLS, but he was funding a lot of different companies that were almost charities to try and divest himself of some of his money in a philanthropic way bless his heart may he rest in peace.
|
|
|
Post by mnkdfann on Apr 9, 2019 20:30:20 GMT -5
Also remember that was 3 years ago when Afrezza was still new. No one had it dialed it in. Now it might be a different story. He could be on it FULL TIME with No pump and No Needles. I'm not a diabetic. So I have no first hand experience with Afrezza. The quote below is from the article. Does it sound like something a full-time Afrezza user would experience? As I said, I wouldn't know, but if it does not then that answers your question. "Aaron mentioned that his CGM was buzzing thanks to the "crazy day" of this announcement, which prompted his blood sugar to spike to 280 so he'd needed an insulin correction dose -- and now his glucose was plummeting rapidly in response to that."
|
|
|
Post by scottmnkd on Apr 9, 2019 20:38:02 GMT -5
Mr. Kowalski could possibly the spokesperson for Afrezza that we have been hoping for - a catalyst for change! Obviously, the man has swagger in the diabetes community and can reach doctors though his personal experiences.
This is good news indeed.
|
|
|
Post by prcgorman2 on Apr 9, 2019 20:42:38 GMT -5
Dr. Kowalski...
|
|
|
Post by nylefty on Apr 9, 2019 21:35:18 GMT -5
Is he on Twitter for someone to ask? ....I am not on Twitter He's on Twitter (@aaronikowalski) but I'm not comfortable with the idea of asking him since I'm not diabetic or a health care professional. Maybe somebody who is one or both will ask him. At the moment his Twitter account is being flooded with congratulatory messages. I got his Twitter address wrong. His middle initial is j, not i. My 85 year-old eyes aren't what they used to be. Sorry. Aaron Kowalski (@aaronjkowalski) · Twitter
twitter.com/aaronjkowalski
Some (big!) personal news: I’m humbled to take on the role as President & CEO of @jdrf, which has played such a key role in T1D advances. Together, we will build on our progress & drive new research more promising than ever before to fight #T1D
|
|
|
Post by sayhey24 on Apr 10, 2019 4:55:25 GMT -5
You’d think Bill Gates or somebody would give us a grant🤷♀️ I find it slightly embarrassing. Thats an interesting thought. Maybe Kevin Johnson and Starbucks should setup a JDRF foundation focused on afrezza use with the kids.
|
|
|
Post by hellodolly on Apr 10, 2019 5:52:35 GMT -5
What do you put the chances that Mike knows Aaron, being from the same community? I would suspect that Mike or MNKD (even Al) had ties to the JDRF. Shouldn't be a big deal for Mike to pickup the phone and congratulate him.
|
|
|
Post by sportsrancho on Apr 10, 2019 6:38:00 GMT -5
MannKind partners with JDRF on pediatric use of Afrezza MannKind Corporation has announced that it signed an agreement with JDRF (formerly the Juvenile Diabetes Research Foundation) to collaborate on research focused on the use of Afrezza inhaled insulin in pediatric diabetes patients. JDRF is the largest non-profit funder of type 1 diabetes research in the world, according to the organization. The FDA approved Afrezza for the treatment of Type 1 and Type 2 diabetes in adults in June 2014. MannKind regained the rights to Afrezza from Sanofi earlier this year and has committed to marketing the product itself. JDRF Chief MIssion Officer and VP or Research Aaron Kowalski commented, “JDRF is pleased to partner with MannKind to explore opportunities to help facilitate making Afrezza more broadly available to the T1D community interested in benefiting from this important therapeutic. MannKind is a fantastic organization focused on addressing the needs of people living with T1D and we look forward to collaborating and continuing to drive research to improve the lives of people with type 1 diabetes.” MannKind Chief Medical Officer Ray Urbanski said, “We are excited to be working with JDRF and the leading scientific experts, community physicians and people with diabetes that are associated with this organization. We have already begun to evaluate Afrezza for use in the pediatric population and we look forward to working with JDRF to advance our mutual interests in advancing therapies for all patients with type 1 diabetes.” www.oindpnews.com/2016/06/mannkind-partners-with-jdrf-on-pediatric-use-of-afrezza/
|
|
|
Post by jlaw277 on Apr 10, 2019 8:53:49 GMT -5
diatribe.org/2019-jdrf-mission-summit-highlights-hope-cure-and-new-t1d-treatments"In addition, Dr. Sherr also shared excitement for using Symlin, an injectable non-insulin treatment approved for both type 1 and type 2 diabetes, and Afrezza, an inhalable insulin. Dr. Kowalski is a believer in a Symlin-insulin combination for automated insulin delivery (AID) systems – Symlin reduces post-meal blood sugar peaks, which makes it well suited for automated insulin delivery. A recent study showed that the combination of insulin and Symlin increased time-in-range by nearly three hours per day (!) compared to insulin-alone AID systems. Afrezza is also being tested in combination with automated insulin delivery, helping to blunt the post-meal increase in blood sugar."
|
|
|
Post by cretin11 on Apr 10, 2019 9:52:18 GMT -5
Having an Afrezza user and proponent as CEO of JDRF is fantastic news. I'm not familiar with how JDRF works, but is being CEO basically a full time position, i.e. will this be his primary day-to-day job? Either way it's great, and hopefully his tenure will be lengthy (at least until we get approval for juvenile use).
|
|
|
Post by mannmade on Apr 10, 2019 10:21:41 GMT -5
Don't get me wrong on this... but I don't think too much will change in the way Dr. Kowalski speaks about Afrezza unless there is a new reason to do so. Dr. K2 (Dr. Kendal being Dr.K1) has used Afrezza for several years while the JDRF's Chief Scientific Officer and is on record saying he likes it a lot. However, let's face it, it has not helped Afrezza too much as of today. I know the JDRF officially supports Afrezza and this may be due to Dr.K2's influence. However, there is no reason to think he will speak more about Afrezza in his new position as he still has a need (if not more so) to remain relatively agnostic to all pharmas and all meds which have a positive impact on treatng diabetes, even if as we all know Afrezza is the best!
|
|
|
Post by buyitonsale on Apr 10, 2019 10:58:25 GMT -5
“JDRF is pleased to partner with MannKind to explore opportunities to help facilitate making Afrezza more broadly available to the T1D community"
Anyone aware of anything that JDRF has actually done so far or helped with?
|
|
|
Post by boca1girl on Apr 10, 2019 12:36:03 GMT -5
“JDRF is pleased to partner with MannKind to explore opportunities to help facilitate making Afrezza more broadly available to the T1D community" Anyone aware of anything that JDRF has actually done so far or helped with? I thought they were directly involved in the pediatric trial somehow, but can’t point to any link.
|
|
|
Post by MnkdWASmyRtrmntPlan on Apr 10, 2019 13:46:52 GMT -5
I agree with Mannmade on his pessimism about Dr. K2 helping Afrezza. Although Dr. Kowalski is a Type 1 that has used Afrezza and an early advocate of CGM’s, he seems to be more interested in JDRF’s big supporter’s pursuits: Glucose-responsive insulin, encapsulation and closed-loop systems. Although he likes Afrezza and thinks it’s “almost” a miracle drug, he does not appear to be using it now, per the statement about his insulin correction causing his glucose to plummet. He also hedged his answer to the Inhaled Insulin question from the video that Sports provided. So, it seems to me that he will most probably be more of an ally to the BP than MNKD.
|
|
|
Post by longliner on Apr 10, 2019 13:50:53 GMT -5
I agree with Mannmade on his pessimism about Dr. K2 helping Afrezza. Although Dr. Kowalski is a Type 1 that has used Afrezza and likes it, and an early advocate of CGM’s, he seems to be more interested in what JDRF’s big supporter’s pursuits: Glucose-responsive insulin, encapsulation and closed-loop systems. Although he likes Afrezza and thinks it’s “almost” a miracle drug, he does not appear to be using it now, per the statement about his insulin correction causing his glucose to plummet. So, it seems to me that he will most probably be more of an ally to the BP than MNKD. What insulin would cause his glucose to plummet as fast as Afrezza?
|
|